Spondyloarthritis & psoriatic arthritis
A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK
Authors' conclusion
In this cohort the highest chance of a positive PsARC response was to 1st line b/tsDMARD: twice the chance of response vs 2nd/3rd line. The chance of a positive PsARC response to 4th+ lines of b/tsDMARD was not significantly different from 2nd/3rd lines after adjustment.
Study context
- Population
- Adults with PsA treated with b/tsDMARDs, routine clinic data from 22 UK hospitals
- Participants
- 1,459 treatment courses
- Exposure
- PsARC response by line of b/tsDMARD therapy: 1st line and 4th+ line vs 2nd/3rd line
- 1st linen = 430
- 2nd/3rd linen = 633reference
- 4th+ linen = 396
- Outcome
- Achieving PsARC response
- Follow-up
- First (12-16 weeks)
Methodological detailsmulticentre, observational, purposive sampling
- Multicentre
- Observational
- Purposive sampling
Main finding
As reported in the abstract
Achieving PsARC · 12-16 weeks
Each group vs 2nd/3rd lineAdjusted odds ratio (95% CI)
1st line
1.91(1.40–2.60)
4th+ line
1.13(0.84–1.55)
Observational data: associations, not effects.
Further findings
Change from baseline TJC/SJC
- No significant difference between 2nd/3rd and 4th+ lines
Original publication
A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK. Rheumatology (Oxford). Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →